Alzheimer disease (AD) is the most common form of dementia, and the central pathogenic event is the abnormal accumulation of amyloid ␤-protein (A␤) in extracellular amyloid deposits and cerebral blood vessels. 1 AD is a complex and genetically heterogeneous disease. Mild cognitive impairment (MCI), a cognitive disorder in the transition between normal cognition and AD, is a known risk factor for AD, with a conversion rate of Ϸ10% per year. 2 Apolipoprotein E (apoE), a lipid transporter, has been found to be contained in amyloid plaques. The apoE4 isoform or APOE ⑀4 allele is associated with the development of AD 1 and an increased risk of MCI. 3 Cholesterol has also been identified as a risk factor for AD 1,4 and MCI. 5 A direct role of cholesterol in the pathogenesis of AD has been suggested by studies in transgenic animal models of AD: cholesterol feeding increases A␤ accumulation and accelerates AD-related pathology, 6 whereas cholesterol lowering with statin reduces A␤ pathology. 7 Although CAD is a prevalent finding in AD, 8 whether or not plasma lipoprotein subfractions are associated with MCI and AD has not yet been investigated. The separation and determination of lipoprotein subfractions are generally labor-intensive and timeconsuming. Recently, however, the research group of Schmitz and coworkers developed a new automated technique to separate and quantify lipoprotein subfractions in minutes using capillary isotachophoresis (cITP). 9,10 Therefore, in the present study, we investigated
the associations among lipoprotein subfractions as determined by cITP, apoE phenotype, MCI, and AD.
Twenty-eight patients with MCI, 47 patients with AD, and 26 nondemented control subjects were evaluated at the Neurology Department of Fukuoka University Hospital between 2002 and 2003. Global cognitive impairment was assessed by the Mini-Mental State Examination (MMSE) 11 and Clinical Dementia Rating (CDR). 12 Patients with MCI (CDRϭ0.5) met the diagnostic criteria for MCI formulated by the Mayo Clinic Alzheimer Disease Research Center (MCADRC) in Rochester, MN. 13 Patients with AD met the National Institute of Neurological and Communicative Disorders and Stroke/ Alzheimer Disease and Related Disorders Association (NINCDS-ADRDA) criteria for probable AD and had a CDR score Ͼ1. Two patients with AD and one patient with MCI received pravastatin. Nondemented control subjects were volunteers who underwent a standard medical check up and were judged to be in good health. They were required to have a CDR score of 0. This study was approved by the Ethics Committee of Fukuoka University, and samples were collected only after the participants had given their informed consent.
ApoE phenotypes were determined by using isoelectric focusing, as described previously, 14 and were confirmed by apoE genotyping. 15 ApoE phenotype-genotype nonconcordance was found in one control subject (E2/E3 and E3/E3), and the results of apoE genotyping were used. Capillary isotachophoresis of plasma lipoproteins was performed on a Beckman P/ACE MDQ system (Beckman-Coulter Inc.) according to the method of Bottcher et al 9 with some modifications, as described previously. 16 Plasma lipoprotein was stained with NBD C6-ceramide (Molecular Probes, Inc.), a lipophilic dye. The peak area for each cITP lipoprotein subfraction relative to that of the internal marker was presented as the level of the cITP lipoprotein. Agarose gel electrophoresis and differential staining were performed using a Rapid Electrophoresis system (REP, Helena Laboratories) according to the method of Kido et al. 17 REP Lipo-30 plate and CHOL/TRIG COMBO (K.K. Helena Kenkyujo) were used as the agarose gel and staining reagents, respectively.
Frequency Distribution of Apolipoprotein E (ApoE) Phenotype, Serum Levels of Total Cholesterol (TC), Low Density Lipoprotein Cholesterol (LDL-C), and ApoB, and Levels of Plasma Lipoprotein Subfractions as Characterized by Capillary Isotachophoresis (cITP) in Nondemented Subjects and Patients With Mild Cognitive Impairment (MCI) and Alzheimer Diseases (AD)
Patients with AD included significantly more females (87.2% versus 61.5%, PϽ0.05), were older (76.9Ϯ0.6 years versus 74.2Ϯ0.9 years), and had lower MMSE scores (18.8Ϯ0.8 versus 29.2Ϯ0.2) than nondemented control subjects. Patients with AD included a significantly higher percentage of subjects carrying the apoE4 isoform than controls and patients with MCI (Table) . Serum levels of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and apoB in patients with both MCI and AD were significantly higher than those in controls as assessed by Scheffe's multiple comparison test (Table) . The differences among groups were significant after adjusting for age and sex by an analysis of covariance (Table) .
The (Figure) . The fLDL and sLDL corresponded to ␤ lipoprotein in agarose gel electrophoresis ( Figure) . The peak area relative to internal marker (RPA) for each lipoprotein fraction in patients with MCI and AD and control subjects is shown in the Table. Patients with AD had a significantly higher RPA for fHDL than control subjects, and patients with both AD and MCI had a significantly higher RPA for sLDL than control subjects. A multiple logistic regression analysis showed that the associations between cITP sLDL and MCI (odds ratio [95% CI]: 10 [2.4 to 40]) and between cITP sLDL and AD (9.6 [2.5 to 48]) were independent of apoE phenotype (PϽ0.01) after adjusting for age and sex.
Lipoprotein profiles as determined by capillary isotachophoresis (left) and lipid profiles as analyzed by agarose gel electrophoresis and differential staining (right) in plasma from a normal healthy subject (A), a patient with mild cognitive impairment (B), and a patient with Alzheimer's disease (C). Peaks 1 to 3, fast (f)-, intermediate (i)-, and slow (s)-migrating HDL; peak 4, chylomicron/remnants; peak 5, VLDL/IDL; peaks 6 to 7, fast-and slowmigrating LDL. This is the first examination of the association between chargedbased LDL subfractions and MCI or AD. Because cITP separates plasma lipoproteins based on electric mobility, the fLDL fraction carries a more-negative electric charge than the sLDL fraction. The electronegative fLDL could be an atherogenic LDL because we found that this LDL fraction inversely correlates with the size of LDL and increases with the oxidation of LDL (unpublished data). We did not detect a significant association between the cITP fLDL subfraction and either MCI or AD, possibly because of the relatively small number of control subjects (Table) . However, we found that the major LDL (sLDL) fraction was associated with both MCI and AD. Our findings support the notion that the increased synthesis of cholesterol is related to the progression of cognitive impairment. Our finding that the association between the cITP sLDL subfraction and AD was independent of the apoE4 isoform is consistent with other reports that the association between the serum TC level and AD is independent of the apoE genotype. 18 Our finding that the cITP sLDL subfraction was increased in both MCI and AD patients suggests that early lipid-lowering therapy in MCI patients could be beneficial, considering that MCI is a known risk factor for AD. In fact, simvastatin has been shown to significantly decrease A␤40 in the cerebrospinal fluid of patients with mild Alzheimer disease, but not in severely affected patients. 19 In conclusion, the charge-based major LDL subfraction as characterized by cITP was associated with both MCI and AD, independent of apoE isoforms, suggesting that the combination of apoE4 and cITP sLDL may be a better indicator of AD than the apoE4 isoform alone. Further large-scale studies are needed to confirm these findings.
